Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02608476 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)
A Phase 3 study, sponsored by Cassiopea SpA.
- Completed
- Registry status
- Phase 3
- Development phase
- 732
- Enrollment target
NCT02608476: Completed Phase 3 study, sponsored by Cassiopea SpA.
NCT02608476 is a Phase 3 study that has completed, run by Cassiopea SpA. The registered enrollment target is 732 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02608476, a Phase 3 study, has completed, sponsored by Cassiopea SpA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 732 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
Primary Outcome
Percentage of subjects in each treatment group achieving "success" at Week 12, with "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.
Interventions
- DRUG Vehicle cream
- DRUG CB-03-01 cream, 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 732 participants |
| Start Date | 2015-11-16 |
| Est. Completion | 2018-02-21 |
| Phase | Phase 3 |
What the finished NCT02608476 record still lists
NCT02608476 is an interventional study that assigns participants to a tested intervention. The registered 732 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Vehicle cream is the first listed.
NCT02608476 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02608476 about?
NCT02608476 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)". The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
What is the current status of trial NCT02608476?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 732 participants. The study started on 2015-11-16. Estimated completion is 2018-02-21.
What interventions are being tested in trial NCT02608476?
The interventions under investigation include: Vehicle cream (DRUG), CB-03-01 cream, 1% (DRUG).
Who is sponsoring clinical trial NCT02608476?
This trial is sponsored by Cassiopea SpA, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02608476's enrollment target sits among peer trials
732 485th of 2000 higher than 1,513 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- NCT07231419 · 734 participants · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI